Nuvalent (NUVL)
(Delayed Data from NSDQ)
$74.11 USD
+1.95 (2.70%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $74.12 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NUVL 74.11 +1.95(2.70%)
Will NUVL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NUVL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NUVL
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
NUVL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Company News for Sep 17, 2024
Other News for NUVL
Decoding Nuvalent Inc (NUVL): A Strategic SWOT Insight
Nuvalent reports Q2 EPS ($1.39), consensus ($1.15)
Nuvalent Inc Reports Q2 2025 EPS of -$1.39, Missing Estimates; Net Loss Reaches $99.7 Million
Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, ...
Paradigm Biocapital Advisors LP Acquires 1,128,613 Shares in Cidara Therapeutics Inc